All News

Oral PCSK9 Inhibitor Enlicitide Meets All End Points in Phase 3 Hypercholesterolemia Trial
September 02, 2025

At week 24, patients receiving once-daily enlicitide demonstrated statistically significant and clinically meaningful reductions in low-density lipoprotein cholesterol compared with placebo.

Overcoming Barriers in Obesity and Hypertension Management: Practical Strategies for Physicians
September 02, 2025

Caissa Troutman, member of the Obesity Medicine Association, emphasizes the importance of shared decision-making in overcoming barriers.

Real-World Study: Semaglutide Lowers Cardiovascular Risk More Than Tirzepatide in Adults With Obesity and CVD
September 02, 2025

At ESC 2025, the STEER study showed semaglutide reduced risk of heart attack, stroke, or death by 57% vs tirzepatide in adults with obesity and cardiovascular disease, complementing prior trial data.

FDA Approves Brensocatib for Non–Cystic Fibrosis Bronchiectasis: Daily Dose
September 02, 2025

Your daily dose of the clinical news you may have missed.

FDA Approves Subcutaneous Leqembi Autoinjector for Maintenance Therapy in Early Alzheimer Disease
September 01, 2025

The FDA has cleared Eisai and Biogen’s Leqembi Iqlik, the first at-home subcutaneous autoinjector for maintenance therapy in patients with early Alzheimer disease.

More Than One-Third of Middle-Aged Adults with Diabetes Prescribed GLP-1 RAs: Daily Dose
September 01, 2025

Your daily dose of the clinical news you may have missed.

Spotting the Subtle Signs of Depression: How Familiarity Helps Family Physicians Excel, With Teresa Lovins, MD
August 29, 2025

Primary care clinicians see a higher share of visits for depression than mental health professionals largely because they know their patients so well, Lovins said.

8 FAQs About Vaccination From Patients With Cardiovascular Disease
August 29, 2025

Based on the FAQ section in the ACC's 2025 Concise Clinical Guidance on vaccination in adults with CVD, this short slideshow also offers recommended answers.

Generic Liraglutide Approved, Marking First Generic GLP-1 RA Indicated Specifically for Weight Management in the US
August 29, 2025

Teva announced approval of the generic formulation of Saxenda, which could help expand access to the extremely popular class of antiobesity medications.

FDA Approves First New Treatment for Fibromyalgia in Over 15 Years: Daily Dose
August 29, 2025

Your daily dose of the clinical news you may have missed.